PDC Therapeutics Announces Poster Presentation at the ESMO 2022 Congress about RS-0139’s ongoing clinical trial on NSCLC
22 August 2022
PDC Therapeutics, a nanomedicines biotech company developing targeted Polymer Drug Conjugates that are aiming to provide cancer patients with an optimal therapeutic index, announced the acceptance of a poster presentation at the ESMO 2022 Congress to be held in person on 9-13 September 2022 in Paris – France.
Poster Title: Phase Ia/Ib study of RS-0139, a novel tumor-targeted delivery of docetaxel, in patients with recurrent, locally advanced, or metastatic non-small cell lung cancer (NSCLC)
Date: 12.09.2022
Location: Poster Area, Hall 4
Poster No: 1200TiP
Presenter: Prof. Dr. Hakan S. Orer, Medical Pharmacology, Koc University Hospital; Dr. Gülşah Nomak, Medical Director, PDC Therapeutics
The poster abstract is available online at the ESMO website.
PDC Therapeutics
PDC Therapeutics is a nanomedicines biotech company, developing targeted Polymer Drug Conjugates that are aiming to provide cancer patients with an optimal therapeutic index for a “Cure with A Smile”. Our nanomedicine pipeline currently houses proprietary programs in various stages of preclinical and clinical development. Cooperating with multinational pharmaceutical companies through co-development programs, PDC therapeutics is supported by an industry experienced board of scientific and supervisory experts around the world. PDC Therapeutics is scientifically backed by RS Research, an academic spin-off which has developed a pioneering class of nanocarriers with targeting capability of different indications.
For detailed information:
